- Q1 2024 Verrica Pharmaceuticals Inc Earnings Call TranscriptMay 13, 2024$9.56 (+19.50%)Earnings
- Q4 2023 Verrica Pharmaceuticals Inc Earnings Call TranscriptFeb 29, 2024$5.27 (-7.87%)Earnings
- Q3 2023 Verrica Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023$3.21 (-9.83%)Earnings
- Verrica Pharmaceuticals Inc to Host KOL Event (Virtual) TranscriptOct 11, 2023
- Verrica Pharmaceuticals Inc to Discuss FDA Approval of YCANTH Call TranscriptJul 24, 2023
- Verrica Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Verrica Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 17, 2023
- Verrica Pharmaceuticals Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Verrica Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 14, 2022
- Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Verrica Pharmaceuticals Inc VIRTUAL PANEL: The Pursuit of Molluscum - Beetlejuice and Nobel Prizes TranscriptSep 22, 2020
Q4 2023 Verrica Pharmaceuticals Inc Earnings Call Transcript
And then yes, good morning, ladies and gentlemen, and welcome to the Veeco Pharmaceuticals Fourth Quarter and Year-end 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded. I'll now turn the call over to our host, Kevin Gordon of LifeSci Advisors. You may begin your conference.
Thank you, operator. Hello, everyone, and welcome to Veritiv Pharmaceuticals Fourth Quarter and Year End 2023 Corporate Update and Earnings Conference Call. With me on the line this morning are Ted White, President and Chief Executive Officer of America pharmaceuticals, go Bonner CorSo, Chief Commercial Officer, Carrie Koehler, Chief Financial Officer, Dr. Gary Goldberg, Americas, Chief Medical Officer, and Chris Hayes, Americas team, Legal Officer.
As a reminder, during today's call, management will make forward looking statements. These statements may include expectations related to the launch and commercialization of Whitecap for the treatment of Luscombe can TGO., some in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)